Merus N v (MRUS) - News Archive

Immunotherapy Advances: SYNC-T for Prostate Cancer and Merus for Head and Neck Cancer In recent developments in cancer therapeutics, innovative immunotherapy treatments have shown promising efficacy, highlighting a tran...

In a significant leap for oncology research and treatment, Merus N.V. an innovative clinical-stage biotechnology company headquartered in Utrecht, The Netherlands, and Cambridge, Massachusetts, has made remarkable strid...

The landscape of oncology is continually evolving, propelled by innovative therapies and clinical trials aimed at addressing hard-to-treat conditions. In a noteworthy development, Merus N.V. (Nasdaq: MRUS), a clinical-s...

In a significant collaboration aimed at addressing the complexities of property transfers and ownership rights, the Federal Home Loan Bank of Indianapolis (FHLBI) and Black Onyx Management recently released the Heirs Ri...

Merus N.V. a clinical-stage immuno-oncology company, has released interim data showcasing the efficacy of its novel antibody, Petosemtamab, in second-line or later (2L+) recurrent/metastatic head and neck squamous cell...

In a significant milestone for cancer treatment, Merus N.V. has received the U.S. Food and Drug Administration (FDA) approval for BIZENGRI (zenocutuzumab-zbco), marking a breakthrough in the fight against advanced pancr...

Merus N.V. a clinical-stage oncology company specializing in the development of innovative multispecific antibodies, has announced significant advancements in its clinical trials for petosemtamab, a novel therapy target...

Leveraging Combination Therapy: Promising Interim Results for Petosemtamab and Pembrolizumab in Oncology In the rapidly evolving landscape of cancer immunotherapy, the combination of different therapeutic agents has bec...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 3, 2024 Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in multispecific antibodies, is making significant strides in the oncology landscape...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in the development of innovative, full-length multispecific antibodies, announced th...

Merus N.V., a clinical-stage oncology company specializing in multispecific antibodies, showcased promising single-agent efficacy results for its investigational therapy MCLA-129 targeting MET exon 14 (METex14) non-smal...

Merus N.V. Announces Pricing of Upsized Public Offering of Common Shares, Raises Approximately $400.2 MillionMerus N.V., a clinical-stage oncology company known for developing innovative full-length multispecific antibo...

Merus N.V. Seeks $300 Million Through Proposed Public Offering of Common SharesUTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 - Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in t...

Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg Being Investigated in Macrophage Activation SyndromeIn an exciting development for the field of rare diseases, biopharmaceutical company Sobi has recently...

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., April 08, 2024 Merus N.V. (Nasdaq: MRUS), a clinical-stage company known for its innovative approach in the development of multispecific antibodies (Biclonics® and Triclon...

Cyprus has joined the ranks of European countries endorsing the use of bioinsecticides, issuing emergency use authorization for Vestaron s SPEAR LEP bioinsecticide. This authorization makes Cyprus the third country with...

Utrecht, The Netherlands, and Cambridge, Mass. - Merus N.V. (Nasdaq: MRUS), a leading clinical-stage oncology company specializing in the development of innovative antibodies for cancer treatment, is thrilled to announc...

In recent studies, Merus N.V., a biopharmaceutical company, announced the acceptance and priority review by the U.S. Food and Drug Administration (FDA) of their biologics license application for Zeno. Zeno is a potentia...

Merus, a leading clinical-stage biotechnology company, recently announced the acceptance of abstracts for presentation at the highly anticipated American Society of Clinical Oncology (ASCO) Annual Meeting of 2024. The c...

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., April 08, 2024 - Merus N.V. (Nasdaq: MRUS), an innovative player in the landscape of clinical-stage oncology, has disclosed intriguing preclinical data revolving around it...